Abstract
CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.
Keywords: CD38, NAD, SIRT1, aging, obesity, metabolic syndrome
Current Pharmaceutical Design
Title: CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Volume: 15 Issue: 1
Author(s): Eduardo Nunes Chini
Affiliation:
Keywords: CD38, NAD, SIRT1, aging, obesity, metabolic syndrome
Abstract: CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.
Export Options
About this article
Cite this article as:
Chini Nunes Eduardo, CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185788
DOI https://dx.doi.org/10.2174/138161209787185788 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myeloperoxidase: The Good, the Bad, and the Ugly
Current Immunology Reviews (Discontinued) Modulation of Protein-Protein Interactions by Stabilizing/Mimicking Protein Secondary Structure Elements
Current Topics in Medicinal Chemistry Shigella Vaccine Development: Prospective Animal Models and Current Status
Current Pharmaceutical Biotechnology Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Current Drug Targets Interleukin 20
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of CD38 in Airway Function
Current Respiratory Medicine Reviews Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma
Combinatorial Chemistry & High Throughput Screening The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Properties and Therapeutic Possibilities for Drugs Acting Upon Endocannabinoid Receptors
Current Drug Targets - CNS & Neurological Disorders Functional Crosstalk Between β2-adrenoreceptor and Muscarinic Acetylcholine Receptor: Implications for Gene-Gene Interactions and Bronchodilatory Responses in Patients with Asthma and COPD
Current Pharmacogenomics and Personalized Medicine Novel Diagnostics R&D for Public Health and Personalized Medicine in Taiwan: Current State, Challenges and Opportunities
Current Pharmacogenomics and Personalized Medicine Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Peripheral Tachykinin Receptors in Neurogenic Inflammation of the Respiratory, Genitourinary and Gastrointestinal Systems
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Effects of Soy Isoflavones in Postmenopausal Women: Clinical Review
Current Drug Therapy n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Vascular Remodelling and Angiogenesis in Asthma: Morphological Aspects and Pharmacological Modulation
Inflammation & Allergy - Drug Targets (Discontinued) How Internet Technology Can Improve the Quality of Care for Substance Use Disorders
Current Drug Abuse Reviews